# Viemed Healthcare Inc. (VMD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $9.08, market value $346 million.

## Valuation
- **P/E (trailing): 25.2×** (5-yr avg 30.2×, 3-yr avg 26.7×). Viemed Healthcare Inc. trades at 25.2× trailing earnings, close to its own five-year average of 30.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.7×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.71**. A PEG of 0.71 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.1×**. Each dollar of revenue is priced at 1.1×.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.5×**. Enterprise value is 6.5× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 8.5%** (5-yr avg 2.7%). Free cash flow equals 8.5% of the market value, above its five-year average of 2.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.0%**. The inverse of the P/E: 4.0% of the price is earned each year.

## Profitability
- **Gross margin: 57.5%**. Viemed Healthcare Inc. keeps 57.5% of revenue after the direct cost of what it sells.
- **Operating margin: 7.5%**. 7.5% of revenue is left after running the business.
- **Net margin: 5.5%**. 5.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.6%**. 10.6% on shareholders' equity is solid.
- **Return on invested capital: 12.8%**. Return on all capital, debt included, is 12.8%.
- **Return on assets: 7.3%**. Each dollar of assets produces 7.3% of profit.

## Growth
- **Revenue growth (1 yr): 20.5%** (3-yr 24.9%/yr, 5-yr 15.5%/yr). Revenue grew 20.5% over the last year, against 15.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 32.1%** (3-yr 32.2%/yr, 5-yr -13.9%/yr). Earnings per share rose 32.1%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 35.0%/yr**. Free cash flow has compounded at 35.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Viemed Healthcare Inc. holds more cash than debt.
- **Altman Z-score: 6.46**. A Z-score of 6.46 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Viemed Healthcare Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (2 analysts). 2 analysts cover Viemed Healthcare Inc.; the consensus is buy, with an average price target of $12.50 (+38% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 33.1%** (YTD 22.2%, 3-mo -8.9%). The shares are up 33.1% over twelve months including dividends.
- **From 52-week high: -28.0%** (50.1% above the low). Trading 28% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 0.31** (volatility 40%). Beta of 0.31 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VMD · Page: https://foliofundamentals.com/stocks/vmd

Not investment advice.